Key result
Immunization schedules involving one or two doses of IPV followed by bOPV failed to maintain a high positive rate for poliovirus type 2-specific antibody, with rates dropping to 35.8% at 24 months in the sIPV-bOPV-bOPV group compared to 100% in the sIPV-sIPV-tOPV group.
Why the study?
Since trivalent OPV was withdrawn and an IPV and bivalent OPV sequential immunization schedule was implemented, no immune persistence data were available for this polio vaccination strategy.
Does sequential immunization with IPV and bOPV maintain long-term poliovirus-specific neutralizing antibody positivity in infants compared to schedules with tOPV?
Observational (n=1,104)
Open-label
No
Does sequential immunization with IPV and bOPV maintain long-term poliovirus-specific neutralizing antibody positivity in infants compared to schedules with tOPV?
Sequential polio immunization schedules with one or two doses of IPV followed by bOPV fail to maintain high seropositivity for type 2 poliovirus at 48 months, indicating a potential need for early booster vaccination.
Answers are grounded in this paper and cite their sources.
bOPV schedules associate with lower type 2 seropositivity at 24 months; hypothesis-generating for boosters, needing prospective confirmation.
Trivalent oral poliovirus vaccine (tOPV) has been withdrawn and instead an inactivated poliovirus vaccine (IPV) and bivalent type 1 and type 3 OPV (bOPV) sequential immunization schedule has been implemented since 2016, but no immune persistence data are available for this polio vaccination strategy. This study aimed to assess immune persistence following different polio sequential immunization schedules. Venous blood was collected at 24, 36, and 48 months of age from participants who had completed sequential schedules of combined IPV and OPV in phase Ⅲ clinical trials. The serum neutralizing antibody titers against poliovirus were determined, and the poliovirus-specific antibody-positive rates were evaluated. A total of 1,104 participants were enrolled in this study. The positive rates of poliovirus type 1- and type 3-specific antibodies among the sequential immunization groups showed no significant difference at 24, 36, or 48 months of age. The positive rates of poliovirus type 2-specific antibody in the IPV-IPV-tOPV group at all time points were nearly 100%, which was significantly higher than the corresponding rates in other immunization groups (IPV-bOPV-bOPV and IPV-IPV-bOPV). Immunization schedules involving one or two doses of IPV followed by bOPV failed to maintain a high positive rate for poliovirus type 2-specific antibody.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) conducted an observational in Polio immunization (n=1,104). Sequential polio immunization schedules (IPV and bOPV) vs. tOPV-containing schedules was evaluated on Poliovirus type 2-specific antibody positive rate at 24, 36, and 48 months of age (p=<0.0001). Immunization schedules involving one or two doses of IPV followed by bOPV failed to maintain a high positive rate for poliovirus type 2-specific antibody, with rates dropping to 35.8% at 24 months in the sIPV-bOPV-bOPV group compared to 100% in the sIPV-sIPV-tOPV group.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: